Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Assets Average (2017 - 2025)

Historic Assets Average for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $182.3 million.

  • Aclaris Therapeutics' Assets Average rose 617.7% to $182.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.3 million, marking a year-over-year increase of 617.7%. This contributed to the annual value of $208.9 million for FY2024, which is 758.16% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Assets Average of $182.3 million as of Q3 2025, which was up 617.7% from $193.6 million recorded in Q2 2025.
  • Aclaris Therapeutics' Assets Average's 5-year high stood at $275.8 million during Q3 2021, with a 5-year trough of $116.1 million in Q1 2021.
  • Over the past 5 years, Aclaris Therapeutics' median Assets Average value was $224.7 million (recorded in 2021), while the average stood at $216.9 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Assets Average soared by 26072.56% in 2021 and then plummeted by 2798.26% in 2024.
  • Aclaris Therapeutics' Assets Average (Quarter) stood at $257.4 million in 2021, then grew by 1.46% to $261.1 million in 2022, then dropped by 20.39% to $207.9 million in 2023, then fell by 3.14% to $201.4 million in 2024, then decreased by 9.45% to $182.3 million in 2025.
  • Its last three reported values are $182.3 million in Q3 2025, $193.6 million for Q2 2025, and $209.2 million during Q1 2025.